CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 22 enrolled
Drug / intervention
Cabozantinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04022343
NCT04022343Phase 2Active
CompareCT.gov

A Phase 2 Study of Neoadjuvant Cabozantinib in Patients With Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma

Emory University·interventional·Posted Jul 17, 2019·Updated May 5, 2026

In Brief

A Phase 2 clinical trial evaluating Cabozantinib for Clear Cell Renal Cell Carcinoma and 2 related conditions. Active but no longer recruiting, targeting 22 participants across 1 site.

Detailed Summary

This phase II clinical trial studies how well cabozantinib works in treating patients with kidney cancer before surgery. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
CountriesUnited States
CollaboratorsExelixis, National Institutes of Health (NIH), National Cancer Institute (NCI)

Timeline

Phase 2Active
20202021202220232024202520262027
First PostedJul 17, 2019
Enrollment StartAug 6, 2019
Primary CompletionFeb 2, 2022
Study CompletionDec 9, 2026
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.0 years ago

Interventions

Cabozantinibdrug

Given PO